Global Specialty Active Pharmaceutical Ingredients (API) Market: Mergers & Acquisitions

Manufacturing specialty active pharmaceutical ingredients (API) continues to be a cost-sensitive task for global leaders in healthcare industry. A key measure undertaken by pharmaceutical companies for reducing operational costs of specialty active pharmaceutical ingredients involves subcontracting the production to contract manufacturing organizations (CMOs). Development of specialty API is being globally carried out by CMO services, enabling drugmakers to accelerate the production of finished pharmaceutical products (FPP), which include tablets, syrups, capsules and others. The demand for specialty active pharmaceutical ingredients keeps surging beyond the production potential, which is why several market players are expanding their businesses through mergers & acquisitions.

Recent happenings in the competitive landscape of global specialty API market project that acquiring CMOs has become a strategic move for pharmaceutical manufacturers invested in active pharmaceutical ingredients production. Lonza Group AG, a global leader in chemicals & biotechnology will be entering the global market for specialty active pharmaceutical ingredients by acquiring Capsugel for reportedly US$ 5.5 billion. The acquisition will help Lonza in being recognized as an integrated solutions provider, specifically for oral drug delivery technologies and active pharmaceutical ingredients. Capsugel’s expertise in specialty active pharmaceutical ingredients will also facilitate the inclusion of upcoming Lonza drugs in consumer healthcare sector and the nutrition industry. Also, the key offerings of Lonza will be augmented by the added value offered from Capsugel’s industry-leading technologies in delivering API-based excipients through multiple dosage methods.

Meanwhile, PLx Pharma Inc. will be merging with Dipexium Pharmaceuticals Inc.’s wholly-owned subsidiary. The all-stock transaction will end up renaming Dipexium as PLx Pharma Inc., and will include the co-marketing of PLx Guard, a delivery system that targets API to several portions of the patient’s gastrointestinal tract. Another significant mergers and acquisitions in the global specialty active pharmaceutical ingredients market include the purchase of BASF’s API businesses in Europe by The Siegfried Group in 2015. In the same year, API supplier Sigma-Aldrich Corp was bought by Merck KGaA for reportedly US$ 17 billion.

According to Future Market Insights’ report, titled “Specialty Active Pharmaceuticals Ingredients (API) Market: Global Industry Analysis & Opportunity Assessment, 2016-2024,” the global market for specialty active pharmaceutical ingredients has witnessed significant contribution from companies namely, Pfizer CenterSource, Almac, Corden Pharma, PolyPeptide Laboratories, Johnson Matthey, Siegfried, AmbioPharm Inc., Pepscan, Provence Technologies Groups, Santaris Pharma, BCN Peptide, SennChemicals AG, Gadea Grupo Farmacéutico, Avecia Oligo Medicines, ST Pharm Oligo Center, FarmaBios Spa, Cepia Sanofi, Symbiotec Pharma Lab Pvt Ltd, STEROID S.p.A, Dextra Laboratories Limited, Dolder AG, Sussex Research, Dalton Pharma Services, GlycoSyn, Noramco Inc., Inalco Pharma, Ash Stevens Fermion (public) Olon SpA, and Pfanstiehl, Inc.

The report also states that the global specialty API market has netted revenues over US$ 119 billion by the end of 2016. Products formed from small molecule API will be accounting for a majority of the global revenues over the forecast period. By the end of 2026, the global specialty API market is also projected to witness growth in revenues from outsourcing the manufacturing of specialty active pharmaceuticals ingredient, which will register a CAGR of over 10%. In terms of region, the global market for specialty active pharmaceutical ingredients will be dominated by North America, considering the prevalence of CMOs, a robust healthcare sector in the US and surplus capital allotted to be expended on production of advanced drugs.

Request For Report Sample with Table of Contents: http://www.futuremarketinsights.com/reports/sample/rep-gb-1719

VN:F [1.9.22_1171]
Rating: 0.0/5 (0 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)


Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends. We provide research services at the global and regional level; key regions include GCC, ASEAN, and BRICS. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and Retail. We have a global presence with delivery centres across India specializing in providing global research reports and country research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery centre located in Pune, India. We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for our client.

No comments.

Leave a Reply

You must be logged in to post a comment.